(Q40464391)

20 September 2017

title

Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses. (English)

1 reference

20 September 2017

Hongxun Sang

1

1 reference

20 September 2017

Vladimir M Pisarev

2

1 reference

20 September 2017

Jennifer Chavez

3

1 reference

20 September 2017

Simon Robinson

4

1 reference

20 September 2017

Yajun Guo

5

1 reference

20 September 2017

Lori Hatcher

6

1 reference

20 September 2017

Corey Munger

7

1 reference

20 September 2017

Cathy B Talmadge

8

1 reference

20 September 2017

Joyce C Solheim

9

1 reference

20 September 2017

Rakesh K Singh

10

1 reference

20 September 2017

James E Talmadge

11

1 reference

20 September 2017

publication date

1 April 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

12

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

427-437

1 reference

p53 mutations in human cancers

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Targeting p53 as a general tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Flt3 ligand (FL) and its influence on immune reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Dendritic cell based tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Generation of potent and specific cellular immune responses via in vivo stimulation of dendritic cells by pNGVL3-hFLex plasmid DNA and immunogenic peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

DNA-encoded fetal liver tyrosine kinase 3 ligand and granulocyte macrophage-colony-stimulating factor increase dendritic cell recruitment to the inoculation site and enhance antigen-specific CD4+ T cell responses induced by DNA vaccination of outbre

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Intramuscular co-injection of naked DNA encoding HBV core antigen and Flt3 ligand suppresses anti-HBc antibody response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Antitumor effect of secreted Flt3-ligand can act at distant tumor sites in a murine model of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Adjuvant effect of a Flt3 ligand (FL) gene-transduced xenogeneic cell line in a murine colon cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

A modified DNA vaccine to p53 induces protective immunity to challenge with a chemically induced sarcoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Suppression of human colorectal carcinoma cell growth by wild-type p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Meeting aims to find brain's benchmarks for beauty

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Flt3 ligand augmentation of T cell mitogenesis and expansion of type 1 effector/memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

Immunotherapy of tumors with vaccines based on xenogeneic homologous molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

p53: a potential target antigen for immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Flt3 ligand induces tumor regression and antitumor immune responses in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Regional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Flt3 ligand pretreatment promotes protective immunity to Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Flt3 ligand and conjugation to IL-1beta peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Second cancer case halts gene-therapy trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700809

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700809

1 reference

Dimensions Publication ID

20 September 2017

1017972372

0 references

1 reference